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Abstract 
The costs associated with current and emerging therapies, as well as 
supportive care, are significant and pose a tremendous financial burden to 
both patients and healthcare system. The objective of this study was to 
calculate the cost savings as a result of bortezomib vial sharing in the 
University Hospital Center “Mother Teresa” Tirana. This study was a 
retrospective analysis of the use of bortezomib in patients with multiple 
myeloma, using vial sharing technique to minimize wastage. The study has 
been conducted during the period January 1, 2015 to June 30, 2015 before 
vial sharing and January 1, 2016 to June 30, 2016 after vial sharing, thereby 
enabling us to share vial contents between patients. We compared the cost in 
euro for the treatment with bortezomib in order to determine the cost savings 
of vial sharing and cost-efficacy of individualised preparation. As a result, the 
cost savings for one cycle/patient using vial sharing was calculated 226.81 
euro, a reduction of 25.96% compared to the period when we did not use vial 
sharing. During January 1, 2015 to June 30, 2015 the average treatment cost 
was calculated 873.36 euro/cycle/patient, compared with January 1, 2016 to 
June 30, 2016 when it was calculated 646.55 euro/cycle/patient. Due to cost 
savings of each treatment cycle we administered 62 individualised 
preparations of bortezomib more during January 1, 2016 to June 30, 2016 for 
the same budget allocated. The same approach should be adopted for other 
suitable drugs prepared in the University Hospital Center “Mother Teresa” 
Tirana.  
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Introduction 
Multiple myeloma is a blood cancer related to lymphoma and leukemia. 
Despite many advances in therapy, there is currently no curative treatment 
available but there are treatments that slow down its spread. Pharmacological 
treatment includes chemotherapy, corticosteroids and targeted therapies such 
as immunomodulators, monoclonal antibodies, proteasome inhibitors, HDAC 
inhibitors and bisphosphonates, which has changed the standards of care for 
affected patients. Although the current achievements in therapy there is a lot 
to be done for patients diagnosed with multiple myeloma to extend their 
survival and to improve their quality of life (Durie, 2010, Laubach, 
Richardson & Anderson, 2010, Ludwig, Beksac, Blade, et al., 2010, 
Richardson, 2010). The advance in cancer knowledge and progresses on 
development of new molecules and treatment schedules offer our patients 
greater expectations in terms of response, prolonged survival, or improved 
quality of life. On the other hand, these new tools are very expensive and the 
availability of resources is limited, so they should be used in an efficient and 
equitable manner (Baselga, & Carrato, 2008). New treatment protocols and 
new classes of drugs are more expensive than the older ones.  
Hence, the costs associated with current and emerging therapies, as 
well as supportive care, are significant and pose a tremendous financial 
burden to both patients and healthcare system (Cook, 2008). This can be an 
obstacle for the treatment of patients with multiple myeloma and sometimes 
the decision related to the treatment of choice is made taking in consideration 
primarily the therapy costs and not the efficacy and clinical outcomes of the 
patients, especially in poor countries and developing countries, where the 
healthcare system financing is low and the budget allocated for drugs is not 
sufficient. Cancer is becoming a major priority for health policies in Albania 
for two major reasons: the increase of mortality and morbidity rates for a 
number of cancers and the delays in diagnosis. The Hematology Department 
of the University Hospital Centre “Mother Teresa” Tirana is the only public 
health structure that offers multidisciplinary treatment for multiple myeloma 
patients in Albania.  
The dose of many anti-cancer medications is calculated based on 
patient weight or body surface area (BSA) (Cheesman, Shields, Shah, et al., 
2016). Although doctors and hospitals sometimes use leftover drug to treat a 
subsequent patient, thus reducing the amount of leftover drug for which they 
bill, this practice is very limited. Safety standards from the US Pharmacopeial 
Convention permit sharing only if leftover drug is used within six hours, and 
only in specialized pharmacies (Smith, 2015, United States Pharmacopeia, 
ed. USP <797> 2008, Fasola, Aprile, Marini, et al., 2014). Cost savings 
approaches are directly related to the drug preparation process. We know that 
most anticancer drugs are individually dosed according to a patient’s body 
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surface and that pharmaceutical products do not exactly fit the dose required 
in a specific patient, generating residual amounts of unused drugs. The waste 
of drugs caused from the vials size also affects the financial costs of the 
treatment. Single-size vials of chemotherapy drugs may be an under noticed 
source of waste and increase in treatment costs. An effective method to reduce 
the drugs waste is the possibility to choose between vials size depending on 
the patient´s need. It is also possible to reduce the waste of drugs using 
individualized preparation. The rational application of personalized dose 
principle may reduce the anticancer drug expenditures (Mertens, & de Jongh, 
2009). Some other possible saving approaches have been proposed, such as 
dose rounding to the nearest vial size (Dooley, Singh, & Michael, 2004), dose 
standardization of anticancer drugs (Pouliquen, Escalup, Jourdan, et al., 2011) 
and selecting the most convenient vial size. In this framework, a project of 
drug waste reduction was designed and launched at the end of 2015 in the 
Hematology Department of the University Hospital Center “Mother Teresa” 
Tirana. The project aimed to estimate the economic benefit and the relative 
influence of the cost savings as a result of vial sharing while respecting drug 
stability. 
Bortezomib (Velcade, Janssen-Cilag, Beerse, Antwerp, Belgium) is a 
drug frequently used in multiple myeloma treatment that is available in 
Albania, U.S.A, Brazil and in many other countries only as a 3.5-mg vial. 
This presentation dose is higher than the average dose commonly prescribed 
and due to the lack of preservatives in the vial, it is mandatory that the drug 
be administered within a couple of hours from the preparation (Mertens, & de 
Jongh, 2009). Bortezomib is available in the U.S.A in only a 3.5 mg vial, 
much larger than the average required dose, which has been calculated to be 
approximately 2.5–2.6 mg based on the drug’s dose of 1.3 mg/m2 and the 
average weight of a cancer patient. It is estimated that 27% to 30% of 
bortezomib sales in the U.S.A are related to leftover drug equating to $309m. 
The drug is sold in 3.5mg and 1 mg vials in the UK (Clark, Castro, Fortes, et 
al., 2011). 
The objective of this study was to calculate the cost savings as a result 
of bortezomib vial sharing in the University Hospital Center “Mother Teresa” 
Tirana, to obtain data for Albania in order to be able in the future to reduce 
furthermore the treatment costs without affecting the clinical outcome of the 
patients and the safety of drugs and to make comparative studies with other 
countries. 
 
Methods 
Study design: This study was a retrospective analysis of the use of 
bortezomib individualised treatment in patients with multiple myeloma, using 
vial sharing technique to minimize wastage, which allows residual amounts 
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of unused drugs to be reused by patients whose treatments are elaborated in 
the same working day, with focus on practicality and cost savings. The study 
was conducted in the period January 1, 2015 to June 30, 2015 before vial 
sharing and January 1, 2016 to June 30, 2016 after vial sharing, thereby 
enabling us to share vial contents between patients and minimize drug 
wastage. Preparation of bortezomib individualized therapy occurred in the 
biosafety cabinet of the Hematology pharmacy in the University Hospital 
Center “Mother Teresa” Tirana. All doses were prepared for administration 
by subcutaneous bolus injection as a dilution of bortezomib in sodium 
chloride 0.9%. In order to protect the patient’s anonymity, the patient’s name 
or any particular characteristic during this study have not been revealed. 
Folders and medical prescriptions of bortezomib were used for this study. The 
Hematology pharmacy calculated the amount of bortezomib needed to 
prepare the prescribed dose, if vials are shared by patients whose treatments 
are elaborated in the same working day. We compared the cost savings in 
euro for the treatment with the same drug for each treatment cycle to calculate 
the total number of cycles and total vials of bortezomib used in the period 
January 1, 2015 to June 30, 2015 in comparison with January 1, 2016 to June 
30, 2016 in order to determine the cost savings and cost-efficacy of the 
individualised preparation and vial sharing. The average cost for each 
bortezomib dose was retrospectively calculated as the average procured price 
in 2015 and 2016, years in which the study was conducted. The mean and 
average calculations were performed based on usual mathematical formulas 
and were represented in euro. The amount of drug wasted was also expressed 
in percentage related to the total content of the 3.5-mg vial. The results of 
costs were expressed in euro with the cost of the 3.5 mg bortezomib vial 
calculated 873.36€ (exchange rate ALL137.4 to €1 as of 2016).  
 
Results 
We evaluated the consequent cost savings of bortezomib vial sharing. 
During the study period, vial consumption data were obtained, absolute 
savings were expressed as number of vials and the cost savings were 
determined using bortezomib calculations. All costs are expressed in euro. 
The cost savings as a result of bortezomib vial sharing for one patient for each 
treatment cycle was calculated 226.81 euro, a reduction of 25.96% compared 
to the period when we didn´t use vial sharing to minimize drug wastage as 
result of the vial size. During the period January 1, 2015 to June 30, 2015 the 
average treatment cost was calculated 873.36 euro/cycle/patient, compared 
with January 1, 2016 to June 30, 2016 when it was calculated 646.55 
euro/cycle/patient. The average required dose of bortezomib, has been 
calculated to be 2.59 mg based on the drug’s dose of 1.3 mg/m2 and the 
average weight of the treated patients. The drug wastage during the period 
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January 1, 2015 to June 30, 2015 was calculated 162.89 mg equivalent to 
46.54 vials of 3.5 mg bortezomib with a total cost of waste estimated to be 
40646.17 euro in comparison with the period January 1, 2016 to June 30, 2016 
in which the drug wastage was calculated 10.2 mg, equivalent to 2.91 vials of 
3.5 mg bortezomib with a total cost of waste estimated to be 2541.47 euro. 
The difference in euro for the drug wastage comparing January 1, 2015 to 
June 30, 2015 and January 1, 2016 to June 30, 2016 was estimated to be 
38104.07 euro equivalent to 46.63 vials of 3.5 mg bortezomib. As a result of 
cost savings due to vial sharing we administered 62 individualized 
preparations of bortezomib more in January 1, 2016 to June 30, 2016 for the 
same budget allocated. Following you can find the calculations for 
bortezomib in Table 1. 
Table 1. Calculations of costs and waste of bortezomib before and after vial 
sharing 
Period of 
time 
Number of 
patients 
treated with 
bortezomib 
Number of 
bortezomib 
vials used 
Cost of 
treatment for 1 
patient/cycle 
Average dose 
of bortezomib 
for 1 
patient/cycle 
Waste in 
mg from 
current 
vial size 
Waste in 
vials of 3.5 
mg 
bortezomib  
Waste in 
euro 
01.01.2015-
30.06.2015 179 179 873.36 € 2.59 mg 162.89 mg 46.54 40,646.17 € 
01.01.2016-
30.06.2016 258 191 646.55 € 2.59 mg 10.2 mg 2.91 2,541.47 € 
 
Discussion 
The rational application of the dose individualization principle based 
on body surface area may result in a substantial reduction in expenditure on 
anticancer drugs (Nava-Ocampo, Alarcon-Almanza, Moyao-Garcia, et al., 
2004) including bortezomib. Drug waste may be defined as the consequence 
of an inappropriate disposal of unused or partially used ampoules, vials, or 
syringes of drugs (Gillerman, & Browning, 2000). It has been previously 
demonstrated that inefficiency of drug use and waste production may lead to 
a distinct economic loss, though experiences are limited and most studies are 
dated or focus on other therapeutic areas (Gillerman, & Browning, 2000, 
Fasola, Aita, Marini, et al., 2008). Decreasing waste is an attractive cost-
cutting strategy because it neither limits specific drug use nor affects quality 
of care (Mertens, & de Jongh, 2009).  
The leftover amount of the used drug depends on the number of 
patients attended, anthropometric characteristics, the time between patients 
who receive the same drug and the marketed vials. One of the main reasons 
for drug waste was essentially the limited extent of chemotherapy medication 
shelf-life and the narrow availability of a range of vial sizes flexibly matching 
with possible drug dosages (Fasola, Aita, Marini, et al., 2008). Therefore, a 
change in the management process would minimize the overall health 
expenditure without adversely impacting patient’s health outcomes. This is 
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one of the biggest future challenges of health systems in the current economic 
environment (Sullivan, Peppercorn, Sikora, et al., 2011). In the last years, 
there has been much discussion on the rising prices of oncologic treatments 
and how much is too much (Meropol, & Schulman, 2007). We believe that 
this discussion is even more important in developing countries, such as 
Albania, which are concerned by a permanently insufficient healthcare 
budget. This analysis intended to give information on how we can reduce 
costs and minimize drug wastage of bortezomib simply with vial sharing 
technique. 
Finally, we think that after the installation of the centralized unit, new 
working habits have been developed. The benefits of this change in paradigms 
into cooperation could be defined as a combination of reaching the goal of 
giving the right drug, with the right dosage, to the right patient, at the right 
time, at a more cost-efficient level. 
 
Conclusion 
Vial sharing of bortezomib between patients combining multiple 
infusions on the same day has improved patient experience by increasing 
access to therapy and reducing waiting times for treatment. Drug costs were 
reduced by 25.96% resulting in significant savings and more patients treated 
with the same amount of vials of bortezomib used. Our experience confirms 
the economic benefit of waste reduction and cost savings effect due to vial 
sharing, especially when used in large centers. The same approach should be 
adopted for other suitable drugs prepared in the bio-safety cabinet in the 
University Hospital Center “Mother Teresa” Tirana. A centralized unit of 
anticancer drug preparation increases the drug traceability from preparation 
to patient. We think that we should initiate a centralization project in the 
University Hospital “Mother Teresa” Tirana in order to reach the goal of “the 
right drug, with the right dosage, to the right patient, at the right time, at the 
right cost”.  
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